Nucleic Acid Sequence and Oncogenic Properties of the HZ2 Feline Sarcoma Virus V-abl Insert

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1987 Apr 1

PMID 3029415

Citations 12

Authors

P J Bergold

J A Blumenthal

E DAndrea

H W Snyder

L Lederman

A Silverstone

H Nguyen

P. Besmer

Affiliations

Soon will be listed here.

Abstract

Hardy-Zuckerman 2 feline sarcoma virus (HZ2-FeSV), isolated from a multicentric feline fibrosarcoma is a replication-defective acute transforming feline retrovirus which originated by transduction of feline c-abl sequences with feline leukemia virus (FeLV) and is known to encode a 110-kilodalton gag-abl fusion protein with tyrosine-specific protein kinase activity (P. Besmer, W. D. Hardy, E. E. Zuckerman, P. J. Bergold, L. Lederman, and H. W. Snyder, Nature (London) 303:825-828, 1983). The nucleotide sequence of the abl segment in the HZ2-FeSV genome was determined and compared with the murine and human v-abl and c-abl sequences. The predicted transforming protein consists of 344 amino acids (aa) of FeLV gag origin, 439 aa of abl origin, and at least 200 aa of FeLV pol origin (p110gag-abl-pol). The 1,317-base-pair HZ2-FeSV v-abl segment (fv-abl) corresponds to 5' abl sequences which include the region known to specify the protein kinase domain. The 5' 189 base pairs of fv-abl correspond to 5' c-abl sequences not contained in Abelson murine leukemia virus (MuLV) v-abl. The mouse c-abl exon which contains these segments was identified, and its nucleotide sequence was determined. Comparison of the predicted amino acid sequence of fv-abl with those of Abelson MuLV v-abl and c-abl revealed five aa differences. The 5' junction between FeLV and abl was found to involve a preferred region in FeLV gag p30 (P. Besmer, J. E. Murphy, P. C. George, F. H. Qiu, P. J. Bergold, L. Lederman, H. W. Snyder, D. Brodeur, E. E. Zuckerman, and W. D. Hardy, Nature (London) 320:415-421, 1986). A six-base homology exists at the recombination site between the parental FeLV and the c-abl sequences. The 3' junction between fv-abl and FeLV pol predicts an in-frame fusion of fv-abl and FeLV pol. A transformed cell line containing a truncated gag-abl-pol protein, p85, that lacks most of the FeLV pol sequences was obtained by transfection of NIH 3T3 mouse cells. This result implies that the pol sequences of the p110gag-abl-pol protein are dispensable for fibroblast transformation. To assess whether the fv-abl segment specifies the unique biological properties of HZ2-FeSV, we constructed a Moloney MuLV-based version of HZ2-FeSV, Mo-MuLV(fv-abl), in which the fv-abl sequences were contained in a genetic context similar to that in HZ2-FeSV.(ABSTRACT TRUNCATED AT 400 WORDS)

Citing Articles

Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.

Rohn J, Lauring A, Linenberger M, Overbaugh J J Virol. 1996; 70(11):8071-80.

PMID: 8892932 PMC: 190881. DOI: 10.1128/JVI.70.11.8071-8080.1996.

3' junctions of oncogene-virus sequences and the mechanisms for formation of highly oncogenic retroviruses.

Zhang J, Temin H J Virol. 1993; 67(4):1747-51.

PMID: 8445707 PMC: 240211. DOI: 10.1128/JVI.67.4.1747-1751.1993.

Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation.

Oppi C, Shore S, Reddy E Proc Natl Acad Sci U S A. 1987; 84(23):8200-4.

PMID: 3317402 PMC: 299509. DOI: 10.1073/pnas.84.23.8200.

Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.

Franz W, Berger P, Wang J EMBO J. 1989; 8(1):137-47.

PMID: 2496972 PMC: 400782. DOI: 10.1002/j.1460-2075.1989.tb03358.x.

Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.

Qiu F, Ray P, Brown K, Barker P, Jhanwar S, Ruddle F EMBO J. 1988; 7(4):1003-11.

PMID: 2456920 PMC: 454427. DOI: 10.1002/j.1460-2075.1988.tb02907.x.

References

Cook W, Metcalf D, Nicola N, Burgess A, Walker F . Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell. 1985; 41(3):677-83. DOI: 10.1016/s0092-8674(85)80048-9. View

Bonner T, Kerby S, Sutrave P, Gunnell M, Mark G, Rapp U . Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol. 1985; 5(6):1400-7. PMC: 366870. DOI: 10.1128/mcb.5.6.1400-1407.1985. View

Jainchill J, Aaronson S, Todaro G . Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol. 1969; 4(5):549-53. PMC: 375908. DOI: 10.1128/JVI.4.5.549-553.1969. View

Abelson H, Rabstein L . Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice. Cancer Res. 1970; 30(8):2208-12. View

Abelson H, Rabstein L . Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 1970; 30(8):2213-22. View

Graham F, Van Der Eb A . A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973; 52(2):456-67. DOI: 10.1016/0042-6822(73)90341-3. View

Scher C, Siegler R . Direct transformation of 3T3 cells by Abelson murine leukaemia virus. Nature. 1975; 253(5494):729-31. DOI: 10.1038/253729a0. View

Rosenberg N, Baltimore D . A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med. 1976; 143(6):1453-63. PMC: 2190217. DOI: 10.1084/jem.143.6.1453. View

Rasheed S, Gardner M, Chan E . Amphotropic host range of naturally occuring wild mouse leukemia viruses. J Virol. 1976; 19(1):13-8. PMC: 354827. DOI: 10.1128/JVI.19.1.13-18.1976. View

10.

Besmer P, Baltimore D . Mechanism of restriction of ecotropic and xenotropic murine leukemia viruses and formation of pseudotypes between the two viruses. J Virol. 1977; 21(3):965-73. PMC: 515635. DOI: 10.1128/JVI.21.3.965-973.1977. View

11.

SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-7. PMC: 431765. DOI: 10.1073/pnas.74.12.5463. View

12.

Gardner M . Type C viruses of wild mice: characterization and natural history of amphotropic, ecotropic, and xenotropic MuLv. Curr Top Microbiol Immunol. 1978; 79:215-59. DOI: 10.1007/978-3-642-66853-1_5. View

13.

Witte O, Rosenberg N, Paskind M, Shields A, Baltimore D . Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A. 1978; 75(5):2488-92. PMC: 392579. DOI: 10.1073/pnas.75.5.2488. View

14.

Witte O, Dasgupta A, Baltimore D . Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature. 1980; 283(5750):826-31. DOI: 10.1038/283826a0. View

15.

Marcu K, Banerji J, Penncavage N, Lang R, Arnheim N . 5' flanking region of immunoglobulin heavy chain constant region genes displays length heterogeneity in germlines of inbred mouse strains. Cell. 1980; 22(1 Pt 1):187-96. DOI: 10.1016/0092-8674(80)90167-1. View

16.

Witte O, Goff S, Rosenberg N, Baltimore D . A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A. 1980; 77(8):4993-7. PMC: 349976. DOI: 10.1073/pnas.77.8.4993. View

17.

Goff S, Gilboa E, Witte O, Baltimore D . Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell. 1980; 22(3):777-85. DOI: 10.1016/0092-8674(80)90554-1. View

18.

Rosenberg N, Clark D, Witte O . Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation. J Virol. 1980; 36(3):766-74. PMC: 353704. DOI: 10.1128/JVI.36.3.766-774.1980. View

19.

Goldfarb M, Weinberg R . Generation of novel, biologically active Harvey sarcoma viruses via apparent illegitimate recombination. J Virol. 1981; 38(1):136-50. PMC: 171133. DOI: 10.1128/JVI.38.1.136-150.1981. View

20.

Zoller M, Nelson N, Taylor S . Affinity labeling of cAMP-dependent protein kinase with p-fluorosulfonylbenzoyl adenosine. Covalent modification of lysine 71. J Biol Chem. 1981; 256(21):10837-42. View